Loading…
Prescription Drug Transparency and Affordability Act
Legislative Progress
Introduced
March 27, 2025
Latest Action
March 27, 2025
Primary Sponsor
Kristen McDonald RivetDemocratic(MI)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
Prescription Drug Transparency and Affordability Act This bill requires pharmacy benefit managers (PBMs) to report, at least once every six months, prescription drug pricing, payment, and utilization data to the health insurance plans for which the PBM provides services. Specifically, a PBM contracted to provide services to an employer or sponsor offering a large group health insurance plan (i.e., a plan with at least 100 employees or participants) must report to the plan certain information for prescription drug claims under the plan. This includes, for each drug, the difference between the compensation paid by the plan to the PBM and the compensation paid by the PBM to the pharmacy. Further, for each therapeutic class of drugs under the plan, a PBM must report (1) the total amount it received in rebates, fees, and discounts; and (2) the net spending for each class after such rebates, fees, and discounts. Each PBM also must report certain information about (1) drugs for which total spending exceeded $10,000; and (2) drugs dispensed through pharmacies affiliated with the plan or PBM, such as the percentage of prescriptions dispensed by such affiliates. Finally, a PBM providing services to any group health insurance plan must provide the plan with a summary document that includes similar information for prescription drug claims under the plan, as determined by the Department of Health and Human Services. Plans must also make certain aggregate summary information available to plan participants. PBMs and plans that violate these requirements are subject to civil penalties.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Health Issues
H.R. 2450/S. 1234 - SSI Savings Penalty Elimination Act H.R. 4771/S. 2438 - Transformation to Competitive Integrated Employment Act H.R. 4644/S. 2459 - ABLE Employment Flexibility Act H.R. 5582/S. 2355 - Patients Deserve Price Tags Act H.R. 1650/S. 763 - Telehealth Expansion Act of 2025 H.R. 9809 - Disabled Access Credit Modernization Act Its Your Money Act - not yet introduced Reform proposals related to the No Surprises Act (originally included as part of the Consolidated Appropriations Act, 2021, P.L. 116-260) Issues related to federal Flexible Spending Accounts, including response to Health Coverage That Works for Everyone: Request for Information from the Senate Finance Committee Dependent Care FSAs - Issues related to the expansion of eligible uses of FSAs(SHRMs Modern CARE Act)
Client expense: $430,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R.1162 - Medicaid Primary Care Improvement Act. S.1944 - Employee Access to Worksite Health Services Act. H.R.2450 - Prescription Drug Transparency and Affordability Act. S.2355 & H.R.5582 - Patients Deserve Price Tags Act. H.R.2199 & S.1173 - Restore Protections for Dialysis Patients Act. Implementation of P.L. 119-21 - One Big Beautiful Bill Act. General health care and employee benefits issues; health care coverage, regulatory implementation, transparency, delivery and payment reform, cost containment, and telehealth. Proposals related to ERISA preemption.
Client expense: $2,700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2026 · third_quarter · Pharmacy
H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans. H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency H.R. 4139 - Cutting Copays Act - Rep. McGarvey, Morgan - Medicare cost-sharing for generic drugs H.R. 4231 - Treat and Reduce Obesity Act - Rep. Kelly, Mike - Medicare coverage of obesity drugs H.R. 4317 - PBM Reform Act - Rep. Carter, Earl L. "Buddy" - PBM contracting requirements and transparency H.R. 4605 - End Prescription Drug Ads Now Act - Rep. Nadler, Jerrold - Ban on DTC drug ads H.R. 4623 - Plain Prescription Prices Act - Rep. Williams, Nikema - Transparency requirements for DTC drug ads H.R. 5094 - Protect Patients from Costly Care Act - Rep. Pappas, Chris - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs H.R. 5526 - Biosimilar Red Tape Elimination Act - Rep. Pfluger, Austin - Biosimilars approval procedures H.R. 6255 - Affordable Insulin Now Act - Rep. Craig, Angie - require cost-sharing for certain insulin products H.R. 7837 - Most Favored Patient Act - Rep. Meuser, Daniel - MFN demonstration H.R. 8779 - PBM Act - Rep. Harshbarger, Diana - PBM ownership requirements H.R. 9661 - Expedited Access to Biosimilars Act - Rep. Langworthy, Nicholas - Biosimilar approval requirements H.R. 10227 - INSULIN Act - Rep. DeGette, Diana - Copay caps H.R. 10369 - Net Effective Cost Transparency and Prescription Drug Affordability Act - Rep. Mackenzie, Ryan - Requirements for PBMs S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manager Transparency Act of 2025 - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval S. 1973 - Treat and Reduce Obesity Act - Sen. Cassidy, Bill - Medicare coverage for obesity drugs S. 2345 - Short on Competition Act - Sen. Klobuchar, Amy - Expedited approval for generic drugs S. 2447 - Repealing the Trump Sick Tax Act - Sen. Welch, Peter - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program S. 2620 - REMEDY Act - Sen. Durbin, Richard - Expedited approvals for certain drug approvals S. 2658 - Medication Affordability and Patient Integrity Act - Sen. Hassan, Maggie - FDA and USPTO coordination S. 3014 - Ensuring Timely Access to Generics Act - Sen. Shaheen, Jeanne - Generic drug approval S. 4332 - Medication Competition Act - Sen. Hassan, Maggie - Pharmaceutical exclusivity periods S. 4355 - Drug Deal Disclosure Act - Sen. Wyden, Ron - Federal MFN agreement transparency S. 4509 - PBM Act - Sen. Warren, Elizabeth - PBM ownership requirements S. 5059 - A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products. - Sen. Moody, Ashley - Biosimilar and biological product review process Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; cost-sharing and coverage of weight loss drugs/GLP-1s; high priced drugs; patent reforms; generic approval; 340B; Most Favored Nation; Pharmacy Benefit Managers; PBM-related issues; step therapy; copay caps; insulin costs; and copay coupons.
Client expense: $3,010,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Protect Medicaid- SSI Savings Penalty Elimination Act (HR 2450/S. 1234) (support); Eliminating the Marriage Penalty in SSI Act (S. 73/HR 7055) (support); Stop the Wait Act of 2025 (HR 930) (support); HCBS Access Act (support)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Retirement
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2026 · third_quarter · Taxation/Internal Revenue Code
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act Child Tax Credit expansion S. 3596/H.R. 10282 Stronger Start for Working Families Act Earned Income Tax Credit reforms
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
H.R.1162 - Medicaid Primary Care Improvement Act. S.1944 - Employee Access to Worksite Health Services Act. H.R.2450 - Prescription Drug Transparency and Affordability Act. S.2355 & H.R.5582 - Patients Deserve Price Tags Act. H.R.2199 & S.1173 - Restore Protections for Dialysis Patients Act. Implementation of P.L. 119-21 - One Big Beautiful Bill Act. General health care and employee benefits issues; health care coverage, regulatory implementation, transparency, delivery and payment reform, cost containment, and telehealth. Proposals related to ERISA preemption.
Client expense: $2,770,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2026 · second_quarter · Pharmacy
Draft, the Expedited Access to Biosimilars Act (no bill number) - Rep. Langworthy, Nick - Biosimilar approval requirements H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans. H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency H.R. 4139 - Cutting Copays Act - Rep. McGarvey, Morgan - Medicare cost-sharing for generic drugs H.R. 4231 - Treat and Reduce Obesity Act - Rep. Kelly, Mike - Medicare coverage of obesity drugs H.R. 4317 - PBM Reform Act - Rep. Carter, Earl L. Buddy - PBM contracting requirements and transparency H.R. 4605 - End Prescription Drug Ads Now Act - Rep. Nadler, Jerrold - Ban on DTC drug ads H.R. 4623 - Plain Prescription Prices Act - Rep. Williams, Nikema - Transparency requirements for DTC drug ads H.R. 5094 - Protect Patients from Costly Care Act - Rep. Pappas, Chris - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs H.R. 5526 - Biosimilar Red Tape Elimination Act - Rep. Pfluger, Austin - Biosimilars approval procedures H.R. 6255 - Affordable Insulin Now Act - Rep. Craig, Angie - require cost-sharing for certain insulin products H.R. 7837 - Most Favored Patient Act - Rep. Meuser, Daniel - MFN demonstration H.R. 8779 - PBM Act - Rep. Harshbarger, Diana - PBM ownership requirements S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manager Transparency Act of 2025 - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval S. 1973 - Treat and Reduce Obesity Act - Sen. Cassidy, Bill - Medicare coverage for obesity drugs S. 2345 - Short on Competition Act - Sen. Klobuchar, Amy - Expedited approval for generic drugs S. 2447 - Repealing the Trump Sick Tax Act - Sen. Welch, Peter - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program S. 2620 - REMEDY Act - Sen. Durbin, Richard - Expedited approvals for certain drug approvals S. 2658 - Medication Affordability and Patient Integrity Act - Sen. Hassan, Margaret - FDA and USPTO coordination S. 3014 - Ensuring Timely Access to Generics Act - Sen. Shaheen, Jeanne - Generic drug approval S. 4332 - Medication Competition Act - Sen. Hassan, Maggie - Pharmaceutical exclusivity periods S. 4355 - Drug Deal Disclosure Act - Sen. Wyden, Ron - Federal MFN agreement transparency S. 4509 - PBM Act - Sen. Warren, Elizabeth - PBM ownership requirements Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; cost-sharing and coverage of weight loss drugs/GLP-1s; high priced drugs; patent reforms; generic approval; Pharmacy Benefit Managers; PBM-related issues; step therapy; copay caps; insulin costs; and copay coupons.
2026 · second_quarter · Medicare/Medicaid
Protect Medicaid- SSI Savings Penalty Elimination Act (HR 2450/S. 1234) (support); Eliminating the Marriage Penalty in SSI Act (S. 73/HR 7055) (support); Stop the Wait Act of 2025 (HR 930) (support)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Taxation/Internal Revenue Code
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act Child Tax Credit expansion S. 3596 Stronger Start for Working Families Act Earned Income Tax Credit reforms
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Retirement
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2026 · first_quarter · Pharmacy
Draft, Expedited Access to Biosimilars Act (no bill number) - Rep. Langworthy, Nick - Biosimilar approval requirements H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans. H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency H.R. 4139 - Cutting Copays Act - Rep. McGarvey, Morgan - Medicare cost-sharing for generic drugs H.R. 4231 - Treat and Reduce Obesity Act - Rep. Kelly, Mike - Medicare coverage of obesity drugs H.R. 4317 - PBM Reform Act - Rep. Carter, Earl L. Buddy - PBM contracting requirements and transparency H.R. 4605 - End Prescription Drug Ads Now Act - Rep. Nadler, Jerrold - Ban on DTC drug ads H.R. 4623 - Plain Prescription Prices Act - Rep. Williams, Nikema - Transparency requirements for DTC drug ads H.R. 5094 - Protect Patients from Costly Care Act - Rep. Pappas, Chris - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs H.R. 6255 - Affordable Insulin Now Act - Rep. Craig, Angie - require cost-sharing for certain insulin products H.R. 7837 - Most Favored Patient Act - Rep. Meuser, Daniel - MFN demonstration S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manager Transparency Act of 2025 - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval S. 1973 - Treat and Reduce Obesity Act - Sen. Cassidy, Bill - Medicare coverage for obesity drugs S. 2345 - Short on Competition Act - Sen. Klobuchar, Amy - Expedited approval for generic drugs S. 2447 - Repealing the Trump Sick Tax Act - Sen. Welch, Peter - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program S. 2620 - REMEDY Act - Sen. Durbin, Richard - Expedited approvals for certain drug approvals Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; cost-sharing and coverage of weight loss drugs/GLP-1s; high priced drugs; patent reforms; Pharmacy Benefit Managers; PBM related issues; and copay coupons.
2026 · first_quarter · Health Issues
H.R.1162 - Medicaid Primary Care Improvement Act. S.1944 - Employee Access to Worksite Health Services Act. H.R.2450 - Prescription Drug Transparency and Affordability Act. S.2355 & H.R.5582 - Patients Deserve Price Tags Act. Implementation of P.L. 119-21 - One Big Beautiful Bill Act. General health care and employee benefits issues; health care coverage, regulatory implementation, transparency, delivery and payment reform, cost containment, and telehealth. Proposals related to ERISA preemption.
Client expense: $2,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2026 · first_quarter · Taxation/Internal Revenue Code
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act Child Tax Credit expansion Newborn Credit engagement S. 3596 Stronger Start for Working Families Act Earned Income Tax Credit reforms
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Retirement
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2026 · first_quarter · Health Issues
H.R. 2450/S. 1234 - SSI Savings Penalty Elimination Act H.R. 4771/S. 2438 - Transformation to Competitive Integrated Employment Act Dependent Care FSAs - Proposals to expand the eligible uses of Dependent Care FSAs and related issues.
Client expense: $360,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
Protect Medicaid- Oppose OBBBA (HR1); SSI Savings Penalty Elimination Act (HR 2450/S. 1234) (support); Eliminating the Marriage Penalty in SSI Act (S. 73/HR 7055) (support); Stop the Wait Act of 2025 (HR 930) (support)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Pharmacy
H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans. H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency H.R. 4139 - Cutting Copays Act - Rep. McGarvey, Morgan - Medicare cost-sharing for generic drugs H.R. 4231 - Treat and Reduce Obesity Act - Rep. Kelly, Mike - Medicare coverage of obesity drugs H.R. 4317 - PBM Reform Act - Rep. Carter, Earl L. Buddy - PBM contracting requirements and transparency H.R. 4605 - End Prescription Drug Ads Now Act - Rep. Nadler, Jerrold - Ban on DTC drug ads H.R. 4623 - Plain Prescription Prices Act - Rep. Williams, Nikema - Transparency requirements for DTC drug ads H.R. 5094 - Protect Patients from Costly Care Act - Rep. Pappas, Chris - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs H.R. 6255 - Affordable Insulin Now Act - Rep. Craig, Angie - require cost-sharing for certain insulin products S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manage Transparency - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval S. 1973 - Treat and Reduce Obesity Act - Sen. Cassidy, Bill - Medicare coverage for obesity drugs S. 2345 - Short on Competition Act - Sen. Klobuchar, Amy - Expedited approval for generic drugs S. 2447 - Repealing the Trump Sick Tax Act - Sen. Welch, Peter - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program S. 2620 - REMEDY Act - Sen. Durbin, Richard - Expedited approvals for certain drug approvals Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; cost-sharing and coverage of weight loss drugs/GLP-1s; high priced drugs; patent reforms; Pharmacy Benefit Managers; PBM related issues; and copay coupons.
2025 · fourth_quarter · Retirement
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act SSA rulemaking engagement
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2025 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act H.R. 353/S. 1382 Family First Act Child Tax Credit expansion Newborn Credit engagement
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
H.R.1 - One Big Beautiful Bill Act and implementation (P.L.119-21). H.R.1026 & S.1719 - Primary Care Enhancement Act of 2025. H.R.1162 - Medicaid Primary Care Improvement Act. H.R.1650 & S.763 - Telehealth Expansion Act of 2025. S.1944 - Employee Access to Worksite Health Services Act. H.R.2450 - Prescription Drug Transparency and Affordability Act. General health care and employee benefits issues; health care coverage, regulatory implementation, transparency, delivery and payment reform, cost containment, and telehealth. Proposals related to ERISA preemption.
Client expense: $2,890,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2025 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act H.R. 353/S. 1382 Family First Act Child Tax Credit expansion Newborn Credit engagement
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Retirement
H.R. 2450/S. 1234 SSI Savings Penalty Elimination Act SSA rulemaking engagement
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2025 · fourth_quarter · Medicare/Medicaid
Protect Medicaid- Oppose OBBBA (HR1); SSI Savings Penalty Elimination Act (HR 2450/S. 1234) (support); Eliminating the Marriage Penalty in SSI Act (S. 73/HR 7055) (support); Stop the Wait Act of 2025 (HR 930) (support)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
H.R. 2450/S. 1234 - SSI Savings Penalty Elimination Act H.R.4771/S. 2438 - Transformation to Competitive Integrated Employment Act H.R. 4644/S. 2459 - ABLE Flexibility Act H.R. 1834 - Breaking the Gridlock Act (Afforadable Care Act Discharge Petitiion)
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
H.R.946, Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R.1262/S.932, Give Kids a Chance Act H.R.1414, Camerons Law H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.1492/S.832, EPIC Act S.527, Prescription Pricing for the People Act H.R.2450, Prescription Drug Transparency and Affordability Act S.882, Patients Before Middlemen Act S.526, Pharmacy Benefit Manager Transparency Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Medicare/Medicaid
Protect Medicaid- Oppose OBBBA (HR1); SSI Savings Penalty Elimination Act (HR 2450/S. 1234) (support); Eliminating the Marriage Penalty in SSI Act (S. 73/HR 7055) (support); Stop the Wait Act of 2025 (HR 930) (support)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Client expense: $3,730,000 · Firm income: Not reported
2025 · second_quarter · Medicare/Medicaid
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
Client expense: $3,730,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Pharmacy
H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency H.R. 4139 - Cutting Copays Act - Rep. McGarvey, Morgan - Medicare cost-sharing for generic drugs H.R. 4231 - Treat and Reduce Obesity Act - Rep. Kelly, Mike - Medicare coverage of obesity drugs H.R. 4317 - PBM Reform Act - Rep. Carter, Earl L. Buddy - PBM contracting requirements and transparency H.R. 4605 - End Prescription Drug Ads Now Act - Rep. Nadler, Jerrold - Ban on DTC drug ads H.R. 4623 - Plain Prescription Prices Act - Rep. Williams, Nikema - Transparency requirements for DTC drug ads H.R. 5094 - Protect Patients from Costly Care Act - Rep. Pappas, Chris - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program H.R. 5197 - Protect Beneficiaries from Middlemen Act - Rep. Malliotakis, Nicole - Medicare cost-sharing limit for drugs S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manage Transparency - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval S. 1973 - Treat and Reduce Obesity Act - Sen. Cassidy, Bill - Medicare coverage for obesity drugs S. 2345 - Short on Competition Act - Sen. Klobuchar, Amy - Expedited approval for generic drugs S. 2447 - Repealing the Trump Sick Tax Act - Sen. Welch, Peter - Repeal of Medicaid cost sharing requirements for drugs; Orphan drug inclusion in Medicare Drug Price Negotiation Program S. 2620 - REMEDY Act - Sen. Durbin, Richard - Expedited approvals for certain drug approvals Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; coverage of weight loss drugs; high priced drugs; patent reforms; Pharmacy Benefit Managers; PBM related issues; and copay coupons.
2025 · third_quarter · Retirement
Support for Family Stability and Opportunity Vouchers Act, Site Neutral Payment Reform Framework, H.R. 2450 / S. 1234 SSI Savings Penalty Elimination Act (support)
Client expense: $20,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Taxation/Internal Revenue Code
Support for H.R. 2450 / S. 1234 SSI Savings Penalty Elimination Act, support for Site Neutral Payment Reform Framework Engagement on HR 1
Client expense: $20,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
H.R.1 - One Big Beautiful Bill Act and implementation (P.L.119-21). H.R.1026 & S.1719 - Primary Care Enhancement Act of 2025. H.R.1162 - Medicaid Primary Care Improvement Act. H.R.1650 & S.763 - Telehealth Expansion Act of 2025. S.1944 - Employee Access to Worksite Health Services Act. H.R.2450 - Prescription Drug Transparency and Affordability Act. General health care and employee benefits issues; health care coverage, regulatory implementation, transparency, delivery and payment reform, cost containment, and telehealth. Proposals related to ERISA preemption.
Client expense: $2,570,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2025 · third_quarter · Health Issues
S. 1041; Affordable Prescriptions for Patients Act S. 1040; Drug Competition Enhancement Act H.R. 3798/ S. 229; Drug-price Transparency for Consumers Act S. 1414; Expedited Access to Biosimilars Act S. 2099; Restore Prescription Drug Discount Act H.R. 5371; Continuing Appropriations and Extension Act H.R. 1; One Big Beautiful Bill Act oAs engrossed in House 5/22/25 oSec. 44123. Ensuring accurate payments to pharmacies under Medicaid. oSec. 44124. Preventing the use of abusive spread pricing in Medicaid. oSec. 44305. Modernizing and Ensuring PBM Accountability. H.R. 2450; Prescription Drug Transparency and Affordability Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 3269; Eliminating Thickets to Increase Competition Act S.2276; Eliminating Thickets to Increase Competition Act H.R. 2214; Delinking Revenue from Unfair Gouging Act S.864: Help Ensure Lower Patients (HELP) Copays Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 832/ H.R. 1492; Ensuring Pathways to Innovative Cures (EPIC) Act S. 1041; Affordable Prescriptions for Patients Act S. 526; Pharmacy Benefit Manager Transparency Act S. 527; Prescription Pricing for the People Act H.R. 2041; Hidden Fee Disclosure Act S.1095; Stop the STALLING Act H.R. 2484; Seniors Access to Critical Medications Act S.229/H.R.3789, the Drug Price Transparency for Consumers Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 5582/S. 2355; Patients Deserve Price Tags Act H.R. 4317; PBM Reform Act H.R. 4623; Plain Prescription Prices Act S. 2620; Reforming Evergreening and Manipulation that Extends Drug Years
Client expense: $2,948,162 · Firm income: Not reported
2025 · third_quarter · Pharmacy
S. 2099; Restore Prescription Drug Discount Act H.R. 1; One Big Beautiful Bill Act oAs engrossed in House 5/22/25 oSec. 44123. Ensuring accurate payments to pharmacies under Medicaid. oSec. 44124. Preventing the use of abusive spread pricing in Medicaid. oSec. 44305. Modernizing and Ensuring PBM Accountability. H.R. 5371; Continuing Appropriations and Extension Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 526; Pharmacy Benefit Manager Transparency Act S. 527; Prescription Pricing for the People Act H.R. 2450; Prescription Drug Transparency and Affordability Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act S. 526; Pharmacy Benefit Manager Transparency Act S. 527; Prescription Pricing for the People Act H.R. 2484; Seniors Access to Critical Medications Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 5582/S. 2355; Patients Deserve Price Tags Act H.R. 4317; PBM Reform Act
Client expense: $2,948,162 · Firm income: Not reported
2025 · third_quarter · Health Issues
Pub. L. 119-21 - One Big Beautiful Bill Act (Reconciliation package: HSA/HDHP provisions) H.R. 2450/S. 1234 - SSI Savings Penalty Elimination Act H.R.4771/S. 2438 - Transformation to Competitive Integrated Employment Act H.R. 4644/S. 2459 - ABLE Flexibility Act
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
H.R.946, Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R.1262/S.932, Give Kids a Chance Act H.R.1414, Camerons Law H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.1492/S.832, EPIC Act S.527, Prescription Pricing for the People Act H.R.2450, Prescription Drug Transparency and Affordability Act S.882, Patients Before Middlemen Act S.526, Pharmacy Benefit Manager Transparency Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Client expense: $3,710,000 · Firm income: Not reported
2025 · second_quarter · Medicare/Medicaid
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
Client expense: $3,710,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Pharmacy
H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 44 - 340B Access Act - Rep. Bergman, Jack - 340B participation expansion H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic drugs applications and approvals H.R. 946 - ORPHAN Cures Act - Rep. Joyce, John - Medicare Drug Negotiation Program H.R. 950 - Saving Seniors Money on Prescriptions Act - Rep. Landsman, Greg - PBM reporting requirements for MA/Part D plans. H.R. 1117 - Responsibility in Drug Advertising Act - Rep. DeLauro, Rosa - Direct-to-consumer ads H.R. 1244 - Reducing Drug Prices for Seniors Act - Rep. Davis, Donald - Coinsurance for Part D drugs H.R. 2214 - DRUG Act - Rep. Miller-Meeks, Mariannette - PBM contracts H.R. 2450 - Prescription Drug Transparency and Affordability Act - Rep. McDonald Rivet, Kristen - PBM transparency H.R. 3493 - Global Fairness in Drug Pricing Act - Rep. Khanna, Ro - Prescription drug international reference pricing H.R. 3546 - Prescription Drug Price Relief Act - Rep. Khanna, Ro - Prescription drug patent reform H.R. 3775 - Fair Prescription Drug Prices for Americans Act - Rep. Van Drew, Jefferson - Prescription drug and biological product international reference pricing H.R. 3789 - DTC Act - Rep. Taylor, David - Direct-to-consumer prescription advertising transparency S. 229 - DTC Act - Sen. Durbin, Richard - Drug advertising requirements S. 483 - Responsibility in Drug Advertising Act - Sen. King, Angus - Drug advertising requirements S. 526 - Pharmacy Benefit Manage Transparency - Sen. Grassley, Chuck - PBM reporting requirements S. 529 - Capping Prescription Costs Act - Sen. Warnock, Raphael - Drug copay caps S. 652 - Protecting Patients from Deceptive Drugs Ads Act - Sen. Durbin, Richard - Drug advertising requirements S. 882 - Patients Before Middlemen Act - Sen. Blackburn, Marsha - PBM reforms S. 891 - Bipartisan Health Care Act - Sen. Wyden, Ron - PBM reforms and transparency S. 1040 - Drug Competition Enhanced Act - Sen. Cornyn, John - Drug patent reform S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act - Sen. Paul, Rand - Biosimilars assessment and approval S. 1587 - Fair Prescription Drug Prices for Americans Act - Sen. Hawley, Josh - Prescription drug international reference pricing S. 1753 - End Price Gouging for Medications Act - Sen. Merkley, Jeff - Prescription drug international reference pricing S. 1818 - Prescription Drug Price Relief Act - Sen. Sanders, Bernard - Prescription drug patent reform S. 1954 - Biosimilar Red Tape Elimination Act - Sen. Lee, Mike - Biological product assessment and approval Issues related to the implementation of Inflation Reduction Act - Medicare negotiation; coverage of weight loss drugs; high priced drugs; patent reforms; Pharmacy Benefit Managers; PBM related issues; and copay coupons.
2025 · second_quarter · Health Issues
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Client expense: $3,490,000 · Firm income: Not reported
2025 · second_quarter · Medicare/Medicaid
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
Client expense: $3,490,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
H.R.1 - One Big Beautiful Bill Act. H.R.1026 & S.1719 - Primary Care Enhancement Act of 2025. H.R.1162 - Medicaid Primary Care Improvement Act. H.R.1650 & S.763 - Telehealth Expansion Act of 2025. H.R.1944 - Employee Access to Worksite Health Services Act. H.R.2450 - Prescription Drug Transparency and Affordability Act. General health care and employee benefits issues; health care coverage, regulatory implementation, transparency, delivery and payment reform, cost containment, and telehealth. Proposals related to ERISA preemption.
Client expense: $3,260,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
S. 1041; Affordable Prescriptions for Patients Act S. 1040; Drug Competition Enhancement Act S. 229; Drug-price Transparency for Consumers Act H.R. 3789; Drug-price Transparency for Consumers Act S. 1414; Expedited Access to Biosimilars Act S. 2099; Restore Prescription Drug Discount Act H.R. 1; One Big Beautiful Bill Act oAs engrossed in House 5/22/25 oSec. 44123. Ensuring accurate payments to pharmacies under Medicaid. oSec. 44124. Preventing the use of abusive spread pricing in Medicaid. oSec. 44305. Modernizing and Ensuring PBM Accountability. H.R. 2450; Prescription Drug Transparency and Affordability Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 3269; Eliminating Thickets to Increase Competition Act H.R. 2214; Delinking Revenue from Unfair Gouging Act S.864: Help Ensure Lower Patients (HELP) Copays Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 832/ H.R. 1492; Ensuring Pathways to Innovative Cures (EPIC) Act S. 1041; Affordable Prescriptions for Patients Act S. 526; Pharmacy Benefit Manager Transparency Act S. 527; Prescription Pricing for the People Act H.R. 2041; Hidden Fee Disclosure Act S.1095; Stop the STALLING Act S. 1302; Increasing Transparency in Generic Drug Application Act H.R. 2484; Seniors Access to Critical Medications Act
Client expense: $3,428,860 · Firm income: Not reported
2025 · second_quarter · Pharmacy
S. 2099; Restore Prescription Drug Discount Act H.R. 1; One Big Beautiful Bill Act oAs engrossed in House 5/22/25 oSec. 44123. Ensuring accurate payments to pharmacies under Medicaid. oSec. 44124. Preventing the use of abusive spread pricing in Medicaid. oSec. 44305. Modernizing and Ensuring PBM Accountability. H.R. 3164; Ensuring Community Access to Pharmacist Service Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 526; Pharmacy Benefit Manager Transparency Act S. 527; Prescription Pricing for the People Act H.R. 2450; Prescription Drug Transparency and Affordability Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act S. 526; Pharmacy Benefit Manager Transparency Act S. 527; Prescription Pricing for the People Act H.R. 2484; Seniors Access to Critical Medications Act
Client expense: $3,428,860 · Firm income: Not reported
2025 · second_quarter · Medicare/Medicaid
Protect Medicaid- Oppose OBBBA (HR1); SSI Savings Penalty Elimination Act (HR 2450/S. 1234) (support); Eliminating the Marriage Penalty in SSI Act (S. 73/HR 7055) (support); Stop the Wait Act of 2025 (HR 930) (support)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Welfare
H.R. 2450 and S. 1234, SSI Savings Penalty Elimination Act, entire bill.
Client expense: $20,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Retirement
Support for Family Stability and Opportunity Vouchers Act, Site Neutral Payment Reform Framework, H.R. 2450 / S. 1234 SSI Savings Penalty Elimination Act (support)
Client expense: $20,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Taxation/Internal Revenue Code
Support for H.R. 2450 / S. 1234 SSI Savings Penalty Elimination Act, support for Site Neutral Payment Reform Framework Engagement on HR 1
Client expense: $20,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Pharmacy
Protecting Pharmacies In Medicaid Act (S. 927) Patients Before Middlemen Act (S. 882) Prescription Drug Transparency and Affordability Act (H.R. 2450)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| HR 1768 |
119th |
| Related bill |
Client expense: $3,010,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $5,320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $4,120,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $4,230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $4,050,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE